GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Press Release

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients 2023-12-11

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients   Ventegra® will list VEGZELMA®(bevacizumab-adcd) on its national formulary that serves more than 400 clients and more than 13 million members and patients in the U.S. Celltrion USA completes a contract ...

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs 2023-10-26

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May ...

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease 2023-10-23

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of i...

게시물 검색
  • 35
    Celltrion Healthcare presents positive results for..
    New two-year data showed that CT-P10 was comparable in terms of overall survival, progression-free survival and sustained response with reference rituximab Data published inTheLancet Haematologydemonstrates therapeutic equivalence of CT…
    2018-12-04
  • 34
    Biosimilars have the potential to deliver dramatic..
    As the global leader in biosimilars, Celltrion Healthcare aims to positively shape future healthcare by improving patient access to biosimilars Monday 19thNovember,00:01am GMT,London, UK –Celltrion Healthcare outlined their vision of ‘shaping fu…
    2018-11-19
  • 33
    Celltrion Healthcare hosts forum with patient advo..
    Barriers to uptake of biosimilars in oncology and how to overcome these were discussed in the context of the introduction of biosimilar trastuzumab for the treatment of breast cancer 22 October 2018 –To coincide with the ESMO 2018 Congress in Muni…
    2018-10-22
  • 32
    UK lags behind most of Europe in access to biologi..
    Global leader in biosimilars, Celltrion Healthcare announces support for the easing of initiation boundaries for biologics that will help the NHS address access inequality Wednesday 5thSeptember 2018, Manchester, UK –Celltrion Healthcare calls for…
    2018-09-05
  • 31
    Celltrion Healthcare showcases promising prelimina..
    The subcutaneous (SC) version of infliximab was comparable in terms of efficacy and safety with intravenous (IV) formulation for the treatment of rheumatoid arthritis up to week 30 indicating that SC version could be a future alternative inflix…
    2018-06-13
  • 30
    Celltrion Healthcare’s new subcutaneous version of..
    Data showed that the subcutaneous (SC) version of infliximab was comparable in terms of efficacy and safety with intravenous (IV) administration of CT-P13 (Remsima®/Inflectra®) As a global leader in biosimilars, Celltrion Healthcare co…
    2018-06-05
  • 29
    Biosimilar trastuzumab candidate, CT-P6, shown to ..
    Biosimilar trastuzumab candidate, CT-P6, shown to be similar in pharmacokinetics to the reference trastuzumab in HER2 positive early breast cancer patients 2 June 2018, Chicago, USAData presented at the2018 American Society of Clinical Oncology …
    2018-06-02
  • 28
    Biosimilars could facilitate early access to life ..
    Payers, physicians and health economists highlighted the importance of biosimilars in improving early access for patients to biological treatment May 21, 2018 07:27 AM Eastern Daylight Time BALTIMORE--(BUSINESS WIRE)--At the International Society…
    2018-05-21
  • 27
    CT-P13 (biosimilar infliximab) is comparable to re..
    PANTS study shows that CT-P13 is an efficacious therapy option when investigating personalised approaches to anti-TNF therapy 17thFebruary 2018, Vienna, Austria –Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study…
    2018-02-17
  • 26
    Celltrion’s Herzuma® (biosimilar trastuzumab) appr..
    Herzuma®(CT-P6) granted EU marketing authorisation to treat early breast cancer, metastatic breast cancer and metastatic gastric cancer WEDNESDAY 14 FEBRUARY, INCHEON, SOUTH KOREA– Celltrion Healthcare today announced that the European Commiss…
    2018-02-15